{"id":"https://openalex.org/W2943395261","doi":null,"title":"Fibroblast-Mediated Resistance to BRAF Inhibition in Metastatic Melanoma - Effect of drugs targeting PI3K/AKT/mTOR signaling pathway","display_name":"Fibroblast-Mediated Resistance to BRAF Inhibition in Metastatic Melanoma - Effect of drugs targeting PI3K/AKT/mTOR signaling pathway","alternate_titles":[],"publication_year":2018,"publication_date":"2018-01-01","ids":{"openalex":"https://openalex.org/W2943395261","mag":"2943395261"},"language":"en","primary_location":{"id":"pmh:https://api.nva.unit.no/publication/019c94b9a8d3-6cc70baa-0fc7-4b32-8cf4-7dc7892842bd","doi":null,"is_oa":true,"landing_page_url":"https://hdl.handle.net/10852/64541","pdf_url":null,"source":{"id":"https://openalex.org/S7407153562","display_name":"NVA (Nasjonalt vitenarkiv)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"info:eu-repo/semantics/masterThesis"},"parent_works":[],"lineage":["https://openalex.org/W2943395261"],"child_works_count":0,"type":"dissertation","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://hdl.handle.net/10852/64541","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5069199466","display_name":"Marta Gawraczynska","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I184942183","display_name":"University of Oslo","ror":"https://ror.org/01xtthb56","country_code":"NO","type":"education","lineage":["https://openalex.org/I184942183"]}],"countries":["NO"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Marta Gawraczynska","raw_affiliation_strings":["Department of Molecular Biosciences, Faculty of Mathematics and Natural Sciences, UNIVERSITY OF OSLO"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Molecular Biosciences, Faculty of Mathematics and Natural Sciences, UNIVERSITY OF OSLO","institution_ids":["https://openalex.org/I184942183"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5069199466"],"corresponding_institution_ids":["https://openalex.org/I184942183"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":0,"reviewed_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/braf-inhibitor-resistance","display_name":"BRAF inhibitor resistance","score":0.7839999794960022},{"id":"https://openalex.org/keywords/metastatic-melanoma","display_name":"metastatic melanoma","score":0.9710000157356262},{"id":"https://openalex.org/keywords/tumor-stroma","display_name":"tumor stroma","score":0.6240000128746033},{"id":"https://openalex.org/keywords/fibroblasts","display_name":"fibroblasts","score":0.8840000033378601},{"id":"https://openalex.org/keywords/pi3k-akt-mtor-pathway","display_name":"PI3K/AKT/mTOR pathway","score":0.9279999732971191},{"id":"https://openalex.org/keywords/erk-signaling","display_name":"ERK signaling","score":0.7839999794960022},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.5450000166893005},{"id":"https://openalex.org/keywords/ck2-inhibitors","display_name":"CK2 inhibitors","score":0.5450000166893005},{"id":"https://openalex.org/keywords/pi3k-inhibitors","display_name":"PI3K inhibitors","score":0.968999981880188},{"id":"https://openalex.org/keywords/mtor-inhibitors","display_name":"mTOR inhibitors","score":0.9950000047683716},{"id":"https://openalex.org/keywords/drug-sensitivity","display_name":"drug sensitivity","score":0.5540000200271606},{"id":"https://openalex.org/keywords/co-culture","display_name":"co-culture","score":0.6650000214576721},{"id":"https://openalex.org/keywords/perk","display_name":"PERK","score":0.5720000267028809},{"id":"https://openalex.org/keywords/ps6","display_name":"pS6","score":0.9729999899864197},{"id":"https://openalex.org/keywords/wi-38-fibroblasts","display_name":"WI-38 fibroblasts","score":0.9520000219345093},{"id":"https://openalex.org/keywords/targeted-therapy","display_name":"targeted therapy","score":0.4650000035762787},{"id":"https://openalex.org/keywords/drug-repurposing","display_name":"drug repurposing","score":0.5389999747276306}],"concepts":[{"id":"https://openalex.org/C86554907","wikidata":"https://www.wikidata.org/wiki/Q285613","display_name":"PI3K/AKT/mTOR pathway","level":3,"score":0.862237811088562},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6707144379615784},{"id":"https://openalex.org/C75217442","wikidata":"https://www.wikidata.org/wiki/Q423650","display_name":"Protein kinase B","level":3,"score":0.6164617538452148},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.4925737977027893},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.4414961636066437},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4255262017250061},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.3561542332172394},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.3124542236328125},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.2207619547843933}],"mesh":[],"locations_count":3,"locations":[{"id":"pmh:https://api.nva.unit.no/publication/019c94b9a8d3-6cc70baa-0fc7-4b32-8cf4-7dc7892842bd","doi":null,"is_oa":true,"landing_page_url":"https://hdl.handle.net/10852/64541","pdf_url":null,"source":{"id":"https://openalex.org/S7407153562","display_name":"NVA (Nasjonalt vitenarkiv)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"info:eu-repo/semantics/masterThesis"},{"id":"pmh:oai:www.duo.uio.no:10852/64541","doi":null,"is_oa":true,"landing_page_url":"http://hdl.handle.net/10852/64541","pdf_url":null,"source":{"id":"https://openalex.org/S7407064446","display_name":"NORA - Norwegian Open Research Archives","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"info:eu-repo/semantics/masterThesis"},{"id":"mag:2943395261","doi":null,"is_oa":false,"landing_page_url":"https://www.duo.uio.no/handle/10852/64541","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":{"id":"pmh:https://api.nva.unit.no/publication/019c94b9a8d3-6cc70baa-0fc7-4b32-8cf4-7dc7892842bd","doi":null,"is_oa":true,"landing_page_url":"https://hdl.handle.net/10852/64541","pdf_url":null,"source":{"id":"https://openalex.org/S7407153562","display_name":"NVA (Nasjonalt vitenarkiv)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"info:eu-repo/semantics/masterThesis"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2943395261.pdf","grobid_xml":"https://content.openalex.org/works/W2943395261.grobid-xml"},"referenced_works_count":83,"referenced_works":["https://openalex.org/W170866122","https://openalex.org/W310079001","https://openalex.org/W1481044359","https://openalex.org/W1508281037","https://openalex.org/W1511924115","https://openalex.org/W1539778282","https://openalex.org/W1904795858","https://openalex.org/W1925840913","https://openalex.org/W1960849084","https://openalex.org/W1963763678","https://openalex.org/W1965766554","https://openalex.org/W1973554995","https://openalex.org/W1981711832","https://openalex.org/W1985424846","https://openalex.org/W1988620734","https://openalex.org/W2007897263","https://openalex.org/W2009096660","https://openalex.org/W2011912935","https://openalex.org/W2012247886","https://openalex.org/W2017566772","https://openalex.org/W2017985095","https://openalex.org/W2024085992","https://openalex.org/W2034550273","https://openalex.org/W2034934174","https://openalex.org/W2044433401","https://openalex.org/W2055624262","https://openalex.org/W2057155063","https://openalex.org/W2058409986","https://openalex.org/W2062809449","https://openalex.org/W2065089882","https://openalex.org/W2065404328","https://openalex.org/W2065626916","https://openalex.org/W2067274009","https://openalex.org/W2078469315","https://openalex.org/W2087690546","https://openalex.org/W2092286514","https://openalex.org/W2093921289","https://openalex.org/W2099881680","https://openalex.org/W2103667120","https://openalex.org/W2105615579","https://openalex.org/W2105660237","https://openalex.org/W2116331370","https://openalex.org/W2117692326","https://openalex.org/W2123080662","https://openalex.org/W2126420121","https://openalex.org/W2127686099","https://openalex.org/W2128542677","https://openalex.org/W2139788242","https://openalex.org/W2139944756","https://openalex.org/W2151181174","https://openalex.org/W2152576550","https://openalex.org/W2157215186","https://openalex.org/W2161366013","https://openalex.org/W2163188200","https://openalex.org/W2165200432","https://openalex.org/W2166498909","https://openalex.org/W2168143310","https://openalex.org/W2168631000","https://openalex.org/W2168711434","https://openalex.org/W2190528488","https://openalex.org/W2266814182","https://openalex.org/W2285588397","https://openalex.org/W2335539125","https://openalex.org/W2407867504","https://openalex.org/W2461628610","https://openalex.org/W2469418432","https://openalex.org/W2471985105","https://openalex.org/W2509811343","https://openalex.org/W2535231956","https://openalex.org/W2535462468","https://openalex.org/W2581414232","https://openalex.org/W2586407709","https://openalex.org/W2587816384","https://openalex.org/W2591628935","https://openalex.org/W2594218383","https://openalex.org/W2619288770","https://openalex.org/W2724221128","https://openalex.org/W2735863468","https://openalex.org/W2760129444","https://openalex.org/W2762347490","https://openalex.org/W2795239550","https://openalex.org/W4244068819","https://openalex.org/W7101116195"],"related_works":["https://openalex.org/W2496110026","https://openalex.org/W2335539125","https://openalex.org/W2740377158","https://openalex.org/W2397235587","https://openalex.org/W2733044522","https://openalex.org/W2465561570","https://openalex.org/W1605988205","https://openalex.org/W1482719134","https://openalex.org/W2891279746","https://openalex.org/W1965614542"],"abstract_inverted_index":{"Introduction.Metastatic":[0],"melanoma":[1,36,105,147,149,233,347,433],"is":[2,46],"an":[3,427],"aggressive":[4],"type":[5],"of":[6,51,59,88,117,188,197,217,276,319,331,339,344,352],"skin":[7],"cancer":[8],"for":[9,430],"which":[10],"the":[11,20,25,39,43,57,77,97,138,154,186,189,195,198,218,221,232,244,261,273,285,299,315,317,328,337,362,364,371,382,396],"incidence":[12],"rate":[13],"has":[14,30],"dramatically":[15],"increased":[16],"worldwide,":[17],"especially":[18],"in":[19,35,102,146,165,223,236,270,298,314,366,390,409],"Scandinavian":[21],"countries.Targeted":[22],"therapy":[23],"with":[24,130,133,153,161,167,214,225,250,278,311,354,368,386,399,416],"BRAF":[26,40],"inhibitor":[27,257],"vemurafenib":[28],"(BRAFi)":[29],"significantly":[31,66],"improved":[32],"clinical":[33,44],"responses":[34],"patients":[37],"carrying":[38],"V600":[41],"mutation.However,":[42],"benefit":[45],"limited":[47],"due":[48],"to":[49,71,184,255],"development":[50],"resistance.Recently,":[52],"our":[53],"group":[54],"demonstrated":[55],"that":[56,289,413],"presence":[58,343],"stromal":[60],"cells,":[61],"such":[62],"as":[63],"fibroblasts,":[64],"can":[65],"influence":[67],"mela":[68],"noma":[69],"sensitivity":[70,101,254],"BRAFi,":[72,251],"indicating":[73,260],"fibroblast-mediated":[74,98,262,264,360,422],"protection":[75,265,423],"from":[76,349],"drug.In":[78],"this":[79,238,256],"master":[80],"project":[81],"we":[82],"investigated":[83],"whether":[84],"using":[85],"a":[86,252],"combination":[87,166,224,274,329,367,397],"BRAFi":[89,131,162,222,277,290,308,320,332,353,365,380,387,415],"and":[90,109,159,179,192,200,206,294,301,323,327,333,373,395,424],"drugs":[91,355],"targeting":[92,356],"PI3K/AKT/mTOR":[93,201,357,374,417],"pathway":[94,418],"could":[95],"eliminate":[96],"protection.Methods.The":[99],"drug":[100],"two":[103],"metastatic":[104],"cell":[106,142,156,212],"lines,":[107],"HM8":[108,205,246],"Melmet":[110,207],"5,":[111],"was":[112,240,258,266,305,309,325,388],"evaluated":[113],"at":[114],"different":[115,172],"doses":[116],"selected":[118],"inhibitors":[119,125,401,419],"(BRAFi,":[120],"CK2i,":[121,134,168,226,279],"PI3Ki":[122,135,169,227,280],"or":[123,129,136,164,170,228,268,281],"mTORi).All":[124],"were":[126,144,151,182,248,283],"used":[127,183],"alone":[128,163],"combined":[132,310],"mTORi.First,":[137],"treatment":[139,330,351,385,398],"effects":[140],"on":[141,321],"viability/proliferation":[143],"tested":[145],"mono-cultures.Subsequently":[148],"cells":[150,209,348],"co-cultured":[152],"fibroblast":[155],"line":[157],"WI-38,":[158],"treated":[160,249],"mTORi.Three":[171],"techniques,":[173],"Western":[174,177],"immunoblotting,":[175],"Simple":[176],"immunoassay":[178],"flow":[180],"cytometry":[181],"investigate":[185],"levels":[187,297,338],"phospho-proteins,":[190],"pERK":[191,293,322],"pS6,":[193],"reflecting":[194],"activity":[196],"MAPK/ERK":[199,372],"signaling":[202,375,393],"pathways.Results.The":[203],"mono-cultured":[204],"5":[208],"showed":[210],"decreased":[211],"viability":[213,235],"increasing":[215],"concentrations":[216],"mono-treatments.In":[219],"addition,":[220],"mTORi":[229,282],"also":[230],"reduced":[231,267,292,336],"cells'":[234],"mono-cultures.However,":[237],"reduction":[239],"mostly":[241],"induced":[242],"by":[243],"BRAFi.When":[245],"co-cultures":[247,271],"lower":[253,326],"observed,":[259],"protection.The":[263],"eliminated":[269],"when":[272,307],"treatments":[275],"used.Finally,":[284],"protein":[286,296],"analysis":[287],"revealed":[288],"strongly":[291],"pS6":[295,324],"mono-cultures,":[300,383],"no":[302],"additional":[303,406],"effect":[304,318],"observed":[306],"CK2i.In":[312],"contrast,":[313],"co-cultures,":[316,363],"CK2i":[334,369],"further":[335],"these":[340],"phospho-proteins.VI":[341],"Conclusions.The":[342],"fibroblasts":[345],"protected":[346],"BRAFi.Combination":[350],"pathway,":[358],"reduced/eliminated":[359],"protection.In":[361],"suppressed":[370],"pathways":[376,394],"more":[377],"efficiently":[378],"than":[379],"mono-treatment.In":[381],"however,":[384],"effective":[389],"suppressing":[391],"both":[392,400],"did":[402],"not":[403],"add":[404],"any":[405],"effec":[407],"t":[408],"suppression.This":[410],"data":[411],"suggest":[412],"combining":[414],"might":[420,425],"overcome":[421],"be":[426],"attractive":[428],"alternative":[429],"treating":[431],"stroma-rich":[432],"tumors.":[434]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2943395261","counts_by_year":[],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2019-05-09T00:00:00"}
